BLSM Insider Trading Activity and SEC Form 4 Filings
BLSM insider trading summary
Over the past 12 months, insiders at BlossomHill Therapeutics, Inc. (BLSM) reported 13 open-market purchases worth $60.2M by 12 insiders and no sales on SEC Form 4. Net insider buying was $60.2M.
Latest BLSM insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 10, 2026 | Carl L Gordon | Director | Buy | $10.0M (625,000 @ $16.00) |
| Aug 10, 2026 | John P. Schmid | Insider | Buy | $96K (6,000 @ $16.00) |
| Aug 10, 2026 | Orbimed Advisors LLC | Director | Buy | $10.0M (625,000 @ $16.00) |
| Aug 10, 2026 | OrbiMed Capital GP VIII LLC | Director | Buy | $10.0M (625,000 @ $16.00) |
| Aug 10, 2026 | Vincent Paul Liptak | General Counsel | Buy | $35K (2,200 @ $16.00) |
| Aug 10, 2026 | Jason A Keyes | Chief Financial Officer | Buy | $11K (700 @ $16.00) |
| Aug 10, 2026 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | $5.0M (312,500 @ $16.00) |
| Aug 10, 2026 | Cormorant Private Healthcare Fund III LP | 10% Owner | Buy | $5.0M (312,500 @ $16.00) |
| Aug 10, 2026 | Cormorant Private Healthcare Fund V LP | 10% Owner | Buy | $5.0M (312,500 @ $16.00) |
| Aug 10, 2026 | Cormorant Private Healthcare Fund VI, LP | 10% Owner | Buy | $5.0M (312,500 @ $16.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.